The data derived from epidemiological and animal models confirm a beneficial effect of fish oil (rich in ω-3 polyunsaturated fatty acids) in the amelioration of tumor growth and progression, including breast cancer. The breast cancer patients often develop bone metastasis evidenced by osteolytic lesions, leading to severe pain and bone fracture. Using a mouse model of MDA-MB-231 human breast cancer cell metastasis to bone, here we show that fish oil diet enriched in DHA (docosahexaenoic acid) and EPA (eicosapentaenoic acid) prevents the formation of osteolytic lesions in bone, indicating suppression of cancer cell metastasis to bone. These results are supported by our data showing both DHA and EPA significantly attenuate the migration/invasion of MDA-MB-231 breast cancer cells in culture. The mechanism that limits breast cancer cells to selective metastasis to bone remains hitherto unexplored. Aberrant increased expression of CD44 is associated with generation of cancer stem cells, which contribute to metastasis of breast cancer cells. We demonstrate that DHA and EPA significantly inhibit the expression of CD44 protein and mRNA by a transcriptional mechanism. Furthermore, we show markedly reduced levels of CD44 mRNA and protein in the tumors of mice, which were fed fish oil diet than those in control diet. Our data provide the first evidence for a salutary effect of fish oil on breast cancer metastasis to bone. Our results identify a novel function of the fish oil active components, DHA and EPA, which target the cell-intrinsic pro-metastatic molecule CD44 to inhibit migration/invasion.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2993881 | PMC |
http://dx.doi.org/10.1016/j.bbrc.2010.10.063 | DOI Listing |
Int J Environ Health Res
January 2025
Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Previous research yields inconsistent findings on the association between air pollution and breast cancer risk, with no definitive causal relationship established. To address this, we conducted a two-sample Mendelian randomization study on data from the IEU open GWAS databases and the Breast Cancer Association Consortium to explore the potential link between air pollution (including PM, PM absorbance, PM, PM, NO, and NO) and breast cancer risk. We found that PM (odds ratio (OR) = 1.
View Article and Find Full Text PDFJ Cancer Res Ther
December 2024
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, People's Republic of China.
Background: The low incidence and poor prognosis primary trastuzumab resistance (PTR) in HER2-positive breast cancer has limited research into possible treatments. Thus, it remains unclear whether this group of patients could benefit from nontargeting HER2 antiangiogenic therapy.
Patients And Methods: We collected the medical data for HER2-positive patients with PTR who received apatinib 250 mg and trastuzumab-based chemotherapy (ATBC) between March 18, 2017, and March 31, 2022.
J Cancer Res Ther
December 2024
School of Chemistry, Chemical Engineering and Life Sciences, Wuhan University of Technology, Wuhan, China.
Tumor-infiltrating lymphocytes (TILs) are key components of the tumor microenvironment (TME) and serve as prognostic markers for breast cancer. Patients with high TIL infiltration generally experience better clinical outcomes and extended survival compared to those with low TIL infiltration. However, as the TME is highly complex and TIL subtypes perform distinct biological functions, TILs may only provide an approximate indication of tumor immune status, potentially leading to biased prognostic results.
View Article and Find Full Text PDFCancer Nurs
January 2025
Author Affiliations: Department Research, Hospital Germans Trias i Pujol, Universitat Autonòma de Barcelona; and NURECARE Research Group, Institut d'Investigació i Hospital Germans Trias i Pujol (IGTP), Ctra de Can Ruti, Camí de les Escoles (Dr Huertas-Zurriaga); Department Research, Institut Català Oncologia-Hospital Germans Trias i Pujol; Universitat Autonòma de Barcelona; GRIN Group, IDIBELL, Institute of Biomedical Research; and NURECARE Research Group, IGTP, Ctra de Can Ruti, Camí de les Escoles (Dr Cabrera-Jaime); Tecnocampus University and NURECARE Research Group, IGTP, Ctra de Can Ruti, Camí de les Escoles (Dr Navarri); Oncology Department, Hereditarian Cancer Program, Institut Català Oncologia-Hospital Germans Trias i Pujol, B-ARGO (Badalona Applied Research Group in Oncology), IGTP (Health Research Institute Germans Trias i Pujol), Universitat Autònoma de Barcelona (Dr Teruel-Garcia); and Nursing Research Group in Vulnerability and Health (GRIVIS); and Nursing Department, Faculty of Medicine, Universitat Autònoma de Barcelona (Dr Leyva-Moral), Badalona, Spain.
Background: Breast cancer survivors face unique challenges in breastfeeding decisions. Limited research exists on the experiences and decision-making processes of young women with breast cancer regarding breastfeeding.
Objective: To explain the decision-making processes of young women with breast cancer in relation to breastfeeding throughout the cancer trajectory.
Breast Cancer Res Treat
January 2025
Department of Oncology, University of Torino, Via Nizza 44, 10126, Turin, Italy.
Purpose: Mammary carcinoma is comprised heterogeneous groups of cells with different metastatic potential. 4T1 mammary carcinoma cells metastasized to heart (4THM), liver (4TLM) and brain (4TBM) and demonstrate cancer-stem cell phenotype. Using these cancer cells we found thatTGF-β is the top upstream regulator of metastatic process.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!